Cedars Sinai Center for the Chronic Pancreatitis Clinical Research Consortium

$574,090U01FY2025DKNIH

Cedars-Sinai Medical Center, West Hollywood CA

Investigators

Linked publications, trials & patents

Paper 39137098 Paper 38825435 Paper 38583544 Paper 38518063 Paper 38461145 Paper 38423226 Paper 38284831 Paper 38047728 Paper 37451493 Paper 37061168 Paper 36940317 Paper 36395395 Paper 36382801 Paper 36206463 Paper 36206462 Paper 36191836 Paper 36149018 Paper 35857066 Paper 35333778 Paper 34728468 Paper 34571258 Paper 34265796 Paper 34156036 Paper 34116939 Paper 34074860 Paper 33590329 Paper 33558189 Paper 33417740 Paper 33132046 Paper 33119154 Paper 32973069 Paper 32813684 Paper 32352677 Paper 32349207 Paper 32285180 Paper 32153416 Paper 32135127 Paper 32132511 Paper 31237889 Paper 31232720 Paper 31227582 Paper 31206467 Paper 31089778 Paper 31066497 Paper 30788684 Paper 30747825 Paper 30705050 Paper 30660726 Paper 30522894 Paper 30325864 Paper 30325862 Paper 30325860 Paper 30325859 Paper 30325858 Paper 30325857 Paper 30325855 Paper 30325854 Paper 30214418 Paper 29917105 Paper 29859950 Paper 29753841 Paper 29596326 Paper 29516037 Paper 29195672 Paper 28958690 Paper 28935577 Paper 28919082 Paper 28847752 Paper 28697126 Paper 28626429 Paper 28501969 Paper 28404095 Paper 28268158 Paper 28194398 Paper 27977625 Paper 27895587 Paper 27855278 Paper 27769811 Paper 27630579 Paper 27609771 Paper 27609706 Paper 27542963 Paper 27428704 Paper 27171516 Paper 26879861 Paper 26658038 Paper 26465949 Paper 26195180

Abstract

This is an application for renewal of Clinical Center designation from the Cedars-Sinai Center for the Chronic Pancreatitis Clinical Research Consortium. The Cedars-Sinai Clinical Center has provided considerable leadership in the organization and progress of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC), the former name of the Consortium. Dr. Pandol co-chairs the Steering Committee and Ancillary and Associated Studies Committee while Dr. Goodarzi co-chairs the T3cDM Working Group and, as chair of the Genetics Committee, leads the Consortiumâs initiatives to define the genetic risks of pancreatitis and T3cDM. We have successfully addressed challenges in recruitment and retention of subjects in the cohort studies to significantly improve our performance, as described in this application. Moreover, we have completed or are performing several ancillary studies including epidemiologic and genetic studies defining the natural history and risk factors for the pancreatic disorders; biomarkers for early diagnosis; and treatment trials based on our mechanistic research of disease mechanisms. For the next phase of the Consortium, we are committed to the following Specific Aims: Aims 1. Continue recruitment and retention of subjects in CPCRC cohort studies (PROCEED, INSPPIRE 2). 2. Continue currently supported ancillary and associated studies elucidating the pathophysiology and testing treatments for pancreatic diseases. 3. Continue a series of studies that combine clinical features with genetic susceptibility to allow for the prediction of future development of diabetes in patients with chronic pancreatitis. 4. Determine the role of pancreatic enzyme replacement in improving glucose homeostasis in patients with chronic pancreatitis and diabetes, with or without pancreatic exocrine pancreatic insufficiency. 5. Develop novel approaches for treatment and symptom management for patients suffering from non- malignant pancreatic diseases. We will carry out the aims with a leading interdisciplinary team committed to collaborative research with other Centers and the Data Coordinating Center (DCC) of the Consortium to continue to address and resolve the outstanding gaps in the field.

View original record on NIH RePORTER →